OS Therapies Incorporated financials
$1.60−0.62%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$28.7M | -$6.8M |
| Net income | -$28.8M | -$8.9M |
| Net margin | — | — |
| Diluted EPS | $-0.98 | $-1.28 |
| EBITDA | -$28.3M | -$6.8M |
| Operating cash flow | -$14.2M | -$7.3M |
| Free cash flow | -$14.7M | -$7.3M |
| Diluted shares | 29.3M | 7.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $269.8K | $5.5M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $100.0K | $100.0K |
| Total assets | $6.8M | $5.5M |
| Total liabilities | $11.9M | $4.7M |
| Shareholders' equity | -$6.1M | -$3.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology